Interferon beta-1b efficacy in real-life clinical setting: a long-term follow-up study (p6.354)
Conclusions:Our post-marketing experience provides further evidence of sustained IFN beta-1b efficacy in modifying the natural course of MS.Disclosure: Dr. Totaro has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva as a speaker. Dr. Di Carmine has nothing to disclose. Dr. Sciamanna has nothing to disclose. Dr. Marini has nothing to disclose. Dr. Carolei has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Totaro, R., Di Carmine, C., Sciamanna, S., Marini, C., Carolei, A. Tags: Disease Modifying Therapy for Multiple Sclerosis: Efficacy and Clinical Trial Outcomes I Source Type: research
MSDx Complex-1: A potential marker of drug response? (P1.406)
Conclusions:MSDx Complex-1 is a candidate biomarker of responders to therapies in MS.Disclosure: Dr. White has received personal compensation for activities with MSDx Inc. as an employee. Dr. Nayak has received personal compensation for activities with MSDx Inc. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: White, V., Nayak, R. Tags: Biomarkers and Experimental Studies for Multiple Sclerosis I Source Type: research
Final results from the BETAPAEDIC study of interferon beta-1b for treatment-naive pediatric patients with relapsing-remitting MS (P1.346)
Conclusions:Final results from BETAPAEDIC suggest that IFNB-1b is an effective treatment with a favorable tolerability profile for pediatric patients with RRMS.Study Supported by: Bayer HealthcareDisclosure: Dr. Gaertner has received personal compensation from Bayer Vital, Biogen, Merck Serono, Teva, and Novartis as a consultant and for honoraria. Dr. Gaertner has received research support from Novartis and Biogen. Dr. Brueck has received personal compensation for activities with Bayer Vital, Biogen, Merck Serono, Teva Pharma, Genzyme, Sanofi Aventis, and Novartis as a lecturer or member of scientific advisory boards. Dr. ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Gartner, J., Bruck, W., Weddige, A., Hummel, H., Norenberg, C., Bugge, J.-P. Tags: Pediatric Multiple Sclerosis Source Type: research
Real-World Monitoring Costs Associated with Initiation of Disease-Modifying Therapy Among Patients with Multiple Sclerosis (P3.401)
Conclusions:Results from this study using real-world claims data indicate significant differences in monitoring costs associated with DMT initiation, with costs generally lowest for GA and highest for NAT. Lower monitoring costs should improve the overall cost–benefit profile of GA compared with other DMTs.Disclosure: Dr. Lage received research support from Teva Pharmaceuticals. Dr. Wu has received personal compensation for activities with Teva Neuroscience as an employee. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Lage, M. L., Wu, Y. Tags: Economic Implications of Multiple Sclerosis Source Type: research
Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms
Conclusion
A better definition of what constitutes a relapse in MS is urgently needed. From a treatment perspective, the management of relapses, particularly in the emergency department (ED), is highly variable. In general, it is possible that patients are treated with steroids based on symptomatology and an ED physician’s evaluation. It is often difficult in the ED to ascertain baseline status or a deviation from it, and an MRI may or may not be performed in the ED owing to cost and availability. However, if objective MRI data are not the singular surrogate biomarker to validate BBB breach, false-positive cases are prob...
Source: Innovations in Clinical Neuroscience - April 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Commentary Current Issue Devices Evaluations Multiple Sclerosis Neurology Technology acute relapse big data blood brain barrier imaging magnetic resonance imaging MRI MS Source Type: research
Ketamine Therapy for Treatment-resistant Depression in a Patient with Multiple Sclerosis: A Case Report
Conclusion—Ketamine may be an alternative treatment for resistant depression and may have a special use in patients with multiple sclerosis.
Introduction
Depression is a frequent finding in patients with multiple sclerosis (MS), with the lifetime prevalence rates for major depressive disorder (MDD) ranging from 36 to 54 percent, more than twice of that in the general population.[1] Even with advances in pharmacological options for treating depression, an estimated 33 to 66 percent of patients with MDD in the general population do not respond to the first antidepressant, and a reported 15 to 33 percent of patients do not ...
Source: Innovations in Clinical Neuroscience - February 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue Depression Multiple Sclerosis Neurology Psychiatry Psychopharmacology Electroconvulsive therapy Ketamine major depressive disorder treatment-resistant depression Source Type: research
Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.
CONCLUSIONS: In this comprehensive meta-analysis of real-world studies in RRMS, Avonex, Rebif and Betaseron had similar clinical profiles. When selecting an IFN, practitioners should consider observational data in their decision making process.
PMID: 28027680 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - December 29, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: multicentric cross-sectional survey in the western balkan countries
Conclusion TS with IFN beta-1b was high in our MS patients. Additionally, these results have demonstrated that patient support program have significant impact on TS with IFN beta-1b in the Balkan cohort of RRMS patients. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 7, 2016 Category: Neurology Source Type: research
Comparative evaluation of patients ’ and physicians’ satisfaction with interferon beta-1b therapy
Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients ’ perception of treatment efficacy. T... (Source: BMC Neurology)
Source: BMC Neurology - September 21, 2016 Category: Neurology Authors: Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler and Michael Hecker Source Type: research
Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options
AbstractMultiple sclerosis (MS) is a chronic, autoimmune, inflammatory, demyelinating disease of the central nervous system. MS is increasingly recognized in the pediatric population, and it is usually diagnosed around 15 years of age. The exact etiology of MS is still not known, although autoimmune, genetic, and environmental factors play important roles in its development, making it a multifactorial disease. The disease in children almost always presents in the relapsing-remittent form. The therapy involves treat ment of relapses, and immunomodulatory and symptomatic treatment. The treatment of children with MS has to ...
Source: Neurology and Therapy - September 16, 2016 Category: Neurology Source Type: research
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
Conclusions:
Although the delay in treatment was relatively short, several clinical outcomes favored earlier treatment. Along with low rates of disability and disease progression in both groups, this supports the value of treatment at CIS.
ClinicalTrials.gov identifier:
NCT01795872.
Classification of evidence:
This study provides Class IV evidence that early compared to delayed treatment prolongs time to CDMS in CIS after 11 years. (Source: Neurology)
Source: Neurology - September 4, 2016 Category: Neurology Authors: Kappos, L., Edan, G., Freedman, M. S., Montalban, X., Hartung, H.-P., Hemmer, B., Fox, E. J., Barkhof, F., Schippling, S., Schulze, A., Pleimes, D., Pohl, C., Sandbrink, R., Suarez, G., Wicklein, E.-M., For the BENEFIT Study Group Tags: Multiple sclerosis ARTICLE Source Type: research
MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon {beta}-1b
Conclusions:
New brain lesions that developed during treatment with GA exhibited evidence of greater FSMTR recovery than during treatment with IFN-β-1b.
Classification of evidence:
This study provides Class III evidence that MTR recovery in patients with MS with new MRI brain lesions is greater with GA than with IFN-β-1b. (Source: Neurology)
Source: Neurology - August 28, 2016 Category: Neurology Authors: Brown, R. A., Narayanan, S., Stikov, N., Cook, S., Cadavid, D., Wolansky, L., Arnold, D. L. Tags: MRI, MTI, Multiple sclerosis ARTICLE Source Type: research
Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon- β treatment in patients with chronic viral cardiomyopathy
ConclusionsImmunomodulatory IFN- β-1b treatment is a well-tolerated and safe treatment option, leading to effective virus clearance or reduction of the virus load in patients with chronic viral cardiomyopathy. Favourable clinical effects assess quality of life, NYHA functional class, and patient global assessment.ClinicalTrials.gov identifier: NCT001185250 (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - August 19, 2016 Category: Cardiology Source Type: research
Care of persons with MS in clinical practice: Management by majority
The mid-1990s saw the advent of a new therapeutic era for multiple sclerosis (MS) with the approval of injectable disease-modifying therapies for relapsing-remitting MS. Despite some differences in routes of injection, frequency of administration, and adverse effects, the 4 initial therapies (interferon-β-1b, interferon-β-1a IM, interferon-β-1a subcutaneous, and glatiramer acetate) were remarkably similar in efficacy and generally safe. In the last 10 years, the landscape has changed dramatically. In addition to the initial 4 injectable therapies and new formulations of 2 of those therapies, 3 oral therapies...
Source: Neurology Clinical Practice - August 14, 2016 Category: Neurology Authors: Marrie, R. A., Racke, M. K. Tags: Multiple sclerosis Editorial Source Type: research
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon {beta}1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)
Conclusions:
Our results suggest that the combination of atorvastatin and interferon β1b is not justified in early relapsing–remitting multiple sclerosis and adds to the body of evidence indicating an absence of significant radiological and clinical benefit of statins in relapsing–remitting multiple sclerosis. (Source: Multiple Sclerosis)
Source: Multiple Sclerosis - July 25, 2016 Category: Neurology Authors: Lanzillo, R., Quarantelli, M., Pozzilli, C., Trojano, M., Amato, M. P., Marrosu, M. G., Francia, A., Florio, C., Orefice, G., Tedeschi, G., Bellantonio, P., Annunziata, P., Grimaldi, L. M., Comerci, M., Brunetti, A., Bonavita, V., Alfano, B., Marini, S., Tags: Original Research Papers Source Type: research
